NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway-Driven Intestinal Neoplasia

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2016 Aug 28

PMID 27566107

Citations 17

Authors

Maria-Magdalena Georgescu

Mihai Gagea

Gilbert Cote

Affiliations

Soon will be listed here.

Abstract

NHERF1/EBP50, an adaptor molecule that interacts with β-catenin, YAP, and PTEN, has been recently implicated in the progression of various human malignancies, including colorectal cancer. We report here that NHERF1 acts as a tumor suppressor in vivo for intestinal adenoma development. NHERF1 is highly expressed at the apical membrane of mucosa intestinal epithelial cells (IECs) and serosa mesothelial cells. NHERF1-deficient mice show overall longer small intestine and colon that most likely could be attributed to a combination of defects, including altered apical brush border of absorbtive IECs and increased number of secretory IECs. NHERF1 deficiency in Apc(Min/+) mice resulted in significantly shorter animal survival due to markedly increased tumor burden. This resulted from a moderate increase of the overall tumor density, more pronounced in females than males, and a massive increase in the number of large adenomas in both genders. The analysis of possible pathways controlling tumor size showed upregulation of Wnt-β-catenin pathway, higher expression of unphosphorylated YAP, and prominent nuclear expression of cyclin D1 in NHERF1-deficient tumors. Similar YAP changes, with relative decrease of phosphorylated YAP and increase of nuclear YAP expression, were observed as early as the adenoma stages in the progression of human colorectal cancer. This study discusses a complex role of NHERF1 for intestinal morphology and presents indisputable evidence for its in vivo tumor suppressor function upstream of Wnt-β-catenin and Hippo-YAP pathways.

Citing Articles

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy.

Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y J Hematol Oncol. 2024; 17(1):46.

PMID: 38886806 PMC: 11184729. DOI: 10.1186/s13045-024-01563-4.

EBP50 Depletion and Nuclear β-Catenin Accumulation Engender Aggressive Behavior of Colorectal Carcinoma through Induction of Tumor Budding.

Itou T, Ishibashi Y, Oguri Y, Hashimura M, Yokoi A, Harada Y Cancers (Basel). 2024; 16(1).

PMID: 38201610 PMC: 10778391. DOI: 10.3390/cancers16010183.

YAP-mediated trophoblast dysfunction: the common pathway underlying pregnancy complications.

Lin Q, Cao J, Yu J, Zhu Y, Shen Y, Wang S Cell Commun Signal. 2023; 21(1):353.

PMID: 38098027 PMC: 10722737. DOI: 10.1186/s12964-023-01371-2.

HPV E6 inhibits E6AP to regulate epithelial homeostasis by modulating keratinocyte differentiation commitment and YAP1 activation.

Yin W, Egawa N, Zheng K, Griffin H, Tian P, Aiyenuro A PLoS Pathog. 2023; 19(6):e1011464.

PMID: 37379354 PMC: 10335691. DOI: 10.1371/journal.ppat.1011464.

Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.

Jordaens S, Oeyen E, Willems H, Ameye F, De Wachter S, Pauwels P Biomolecules. 2023; 13(6).

PMID: 37371512 PMC: 10296596. DOI: 10.3390/biom13060932.

References

Kreimann E, Morales F, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu T . Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene. 2007; 26(36):5290-9. DOI: 10.1038/sj.onc.1210336. View

Hayashi Y, Molina J, Hamilton S, Georgescu M . NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia. 2010; 12(12):1013-22. PMC: 3003136. DOI: 10.1593/neo.10780. View

Sansom O, Reed K, van de Wetering M, Muncan V, Winton D, Clevers H . Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem. 2005; 280(31):28463-7. DOI: 10.1074/jbc.M500191200. View

Mayasundari A, Ferreira A, He L, Mahindroo N, Bashford D, Fujii N . Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. Bioorg Med Chem Lett. 2008; 18(3):942-5. DOI: 10.1016/j.bmcl.2007.12.038. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Broere N, Hillesheim J, Tuo B, Jorna H, Houtsmuller A, Shenolikar S . Cystic fibrosis transmembrane conductance regulator activation is reduced in the small intestine of Na+/H+ exchanger 3 regulatory factor 1 (NHERF-1)- but Not NHERF-2-deficient mice. J Biol Chem. 2007; 282(52):37575-84. DOI: 10.1074/jbc.M704878200. View

Philipp-Staheli J, Kim K, Payne S, Gurley K, Liggitt D, Longton G . Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell. 2002; 1(4):355-68. DOI: 10.1016/s1535-6108(02)00054-5. View

Haigis K, Hoff P, White A, Shoemaker A, Halberg R, Dove W . Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function. Proc Natl Acad Sci U S A. 2004; 101(26):9769-73. PMC: 470749. DOI: 10.1073/pnas.0403338101. View

Cuello-Carrion F, Troncoso M, Guinazu E, Valdez S, Fanelli M, Ciocca D . Estrogens regulate the expression of NHERF1 in normal colon during the reproductive cycle of Wistar rats. Histochem Cell Biol. 2010; 134(6):623-30. DOI: 10.1007/s00418-010-0762-2. View

10.

Boivin G, Washington K, Yang K, Ward J, Pretlow T, Russell R . Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003; 124(3):762-77. DOI: 10.1053/gast.2003.50094. View

11.

Georgescu M, Morales F, Molina J, Hayashi Y . Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 2008; 8(6):459-68. DOI: 10.2174/156652408785748031. View

12.

Kremer K, Dudakovic A, Hess A, Smith B, Karp J, Kaufmann S . Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts. J Biol Chem. 2015; 290(49):29478-92. PMC: 4705949. DOI: 10.1074/jbc.M115.668160. View

13.

Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S . YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014; 158(1):157-70. DOI: 10.1016/j.cell.2014.06.013. View

14.

Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu M . PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003; 23(17):6139-49. PMC: 180959. DOI: 10.1128/MCB.23.17.6139-6149.2003. View

15.

Fitzpatrick J, Pellegrini M, Cushing P, Mierke D . Small molecule inhibition of the Na(+)/H(+) exchange regulatory factor 1 and parathyroid hormone 1 receptor interaction. Biochemistry. 2014; 53(37):5916-22. PMC: 4172209. DOI: 10.1021/bi500368k. View

16.

Georgescu M, Cote G, Agarwal N, White 3rd C . NHERF1/EBP50 controls morphogenesis of 3D colonic glands by stabilizing PTEN and ezrin-radixin-moesin proteins at the apical membrane. Neoplasia. 2014; 16(4):365-74.e1-2. PMC: 4094837. DOI: 10.1016/j.neo.2014.04.004. View

17.

Pinto D, Clevers H . Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res. 2005; 306(2):357-63. DOI: 10.1016/j.yexcr.2005.02.022. View

18.

Yoshida M, Zhao L, Grigoryan G, Shim H, He P, Yun C . Deletion of Na+/H+ exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24. Am J Physiol Gastrointest Liver Physiol. 2016; 310(8):G586-98. PMC: 4836134. DOI: 10.1152/ajpgi.00419.2015. View

19.

Wang S, Raab R, Schatz P, Guggino W, Li M . Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR). FEBS Lett. 1998; 427(1):103-8. DOI: 10.1016/s0014-5793(98)00402-5. View

20.

Su L, Kinzler K, Vogelstein B, Preisinger A, Moser A, Luongo C . Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992; 256(5057):668-70. DOI: 10.1126/science.1350108. View